research Docking and Molecular Dynamics Identify Leads against 5 Alpha Reductase 2 for Benign Prostate Hyperplasia Treatment
New compounds show promise for treating benign prostate hyperplasia with fewer side effects.
Search
for
Sort by
Research
300-330 / 1000+ resultsresearch 5 Alpha-reductase inhibitors: whatʼs new?
A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.
research Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children
Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
research Identification of xenobiotics interfering with 5 α -reductase (SRD5A2) activity
MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
research Disappearance of a virilizing adrenal tumor following therapy with cyproterone acetate
A woman's adrenal tumor disappeared after treatment with cyproterone acetate.
research Finasteride
research Histological and immunohistochemical examination of the effect of the nonsteroidal antiandrogen {flutamide} on some organs of the male reproductive system in albino rats
Flutamide caused damage to male rat reproductive organs and may affect fertility.
research Finasteride, dutasteride: potential risk of suicidal ideation
research Finasteride with Doxazosin to Reduce BPH Progression
research Synthesis of 17β-N-arylcarbamoylandrost-4-en-3-one derivatives and their anti-proliferative effect on human androgen-sensitive LNCaP cell line
Compounds 6f and 6g effectively stop prostate cancer cell growth without harming healthy cells.
research MP85-05 SEXUAL DYSFUNCTION AFTER 5-ALPHA REDUCTASE INHIBITOR USE: INSIGHTS FROM THE REDUCE STUDY GROUP DATABASE
Dutasteride use can lead to a stable decline in sexual function that is not affected by age or prostate size.
research Identification of Anabolic Selective Androgen Receptor Modulators with Reduced Activities in Reproductive Tissues and Sebaceous Glands
Two new compounds were found to build bone and muscle without affecting reproductive organs and skin oil glands.
research Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite
Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
research Drug safety evaluation of exemestane
Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
research PD02-05 SRD5A2 EXPRESSION IS A PREDICTOR OF RESPONSE TO FINASTERIDE IN THE MTOPS TRIAL
Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.
research EFFECT OF A COMBINATION OF DUTASTERIDE AND PARENTERAL TESTOSTERONE UNDECANOATE ON TESTOSTERONE DEFICIENCY SYMPTOMS AND PROSTATE IN PATIENTS WITH TESTOSTERONE DEFICIENCY AND BENIGN PROSTATIC HYPERPLASIA
The combination treatment reduced prostate size and improved testosterone deficiency symptoms but was less effective for sexual function.
research New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics
New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.
research Ezetimibe Reduces Enlarged Prostate in an Animal Model of Benign Prostatic Hyperplasia
Ezetimibe effectively reduces prostate size in cases of benign prostatic hyperplasia.
research Synthesis, antiproliferative activity, acute toxicity and assessment of the antiandrogenic activities of new androstane derivatives
research Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
research Imported cutaneous Leishmaniasis in Japan
Albendazole can cause hair loss, and piroxicam can cause fixed drug eruption.
research Recent Advances in the Chemistry and Pharmacological Activity of New Steroidal Antiandrogens and 5α-Reductase Inhibitors
New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
research Tamoxifen-induced androgenetic alopecia in a dialysis patient with sclerosing encapsulating peritonitis (SEP)
research Role of allopregnanolone biosynthesis in acute stress-induced anxiety-like behaviors in mice
Blocking allopregnanolone production in mice makes them more anxious after stress, but this can be reversed with a drug that mimics allopregnanolone.
research Management of Advanced Prostate Cancer Undergoing Major Shift
New treatments are making advanced prostate cancer management more complex but also more hopeful.
research Dutasteride nanoemulsion preparation to inhibit 5-alpha-hair follicle reductase enzymes in the hair follicle; an ex vivo study.
The dutasteride nanoemulsion could improve hair loss treatment by enhancing drug penetration and retention in hair follicles.
research Ginecomastia por finasteride
research Therapeutic Androgen Receptor Ligands
Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.
research Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review
Dutasteride works better than finasteride for hair loss and has mild, reversible side effects.
research A new combination of molecules for the treatment of androgenetic alopecia and telogen effluvium: a double-blind randomized, monocentric, placebo-controlled study
The combination of arginine and zinc reduces hair loss and increases hair growth effectively.